<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="pmc-domain-id">2604</journal-id><journal-id journal-id-type="pmc-domain">ofid</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8802796</article-id><article-id pub-id-type="pmcid-ver">PMC8802796.1</article-id><article-id pub-id-type="pmcaid">8802796</article-id><article-id pub-id-type="pmcaiid">8802796</article-id><article-id pub-id-type="pmid">35111872</article-id><article-id pub-id-type="doi">10.1093/ofid/ofab649</article-id><article-id pub-id-type="publisher-id">ofab649</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Major Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00290</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetic Evaluation of Cefazolin in the Cerebrospinal Fluid of Critically Ill Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Novak</surname><given-names initials="AR">Alison R</given-names></name><xref rid="AF0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1746-7462</contrib-id><name name-style="western"><surname>Krsak</surname><given-names initials="M">Martin</given-names></name><xref rid="AF0002" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7415-3999</contrib-id><name name-style="western"><surname>Kiser</surname><given-names initials="TH">Tyree H</given-names></name><xref rid="AF0003" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Neumann</surname><given-names initials="RT">Robert T</given-names></name><xref rid="AF0004" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cava Prado</surname><given-names initials="L">Luis</given-names></name><xref rid="AF0004" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6764-5984</contrib-id><name name-style="western"><surname>Molina</surname><given-names initials="KC">Kyle C</given-names></name><xref rid="AF0001" ref-type="aff">1</xref><xref rid="AF0002" ref-type="aff">2</xref><xref rid="AF0003" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1238-8199</contrib-id><name name-style="western"><surname>Mueller</surname><given-names initials="SW">Scott W</given-names></name><xref rid="AF0001" ref-type="aff">1</xref><xref rid="AF0003" ref-type="aff">3</xref><xref rid="c1" ref-type="corresp"/></contrib></contrib-group><aff id="AF0001"><label>1</label>
<institution>Department of Pharmacy, UCHealth - University of Colorado Hospital</institution>, <addr-line>Aurora, Colorado</addr-line>, <country country="US">USA</country></aff><aff id="AF0002"><label>2</label>
<institution>Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine</institution>, <addr-line>Aurora, Colorado</addr-line>, <country country="US">USA</country></aff><aff id="AF0003"><label>3</label>
<institution>Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus</institution>, <addr-line>Aurora, Colorado</addr-line>, <country country="US">USA</country></aff><aff id="AF0004"><label>4</label>
<institution>Division of Neurosurgery, Department of Medicine, University of Colorado School of Medicine</institution>, <addr-line>Aurora, Colorado</addr-line>, <country country="US">USA</country></aff><author-notes><corresp id="c1">Correspondence: Scott Mueller, PharmD, FCCM, FCCP, 12850 East Montview Boulevard, Mail Stop C238, Aurora, CO 80045 (<email>scott.mueller@uchealth.org</email>).</corresp></author-notes><pub-date pub-type="collection"><month>2</month><year>2022</year></pub-date><pub-date pub-type="epub" iso-8601-date="2021-12-25"><day>25</day><month>12</month><year>2021</year></pub-date><volume>9</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">398994</issue-id><elocation-id>ofab649</elocation-id><history><date date-type="received"><day>10</day><month>11</month><year>2021</year></date><date date-type="accepted"><day>24</day><month>12</month><year>2021</year></date><date date-type="editorial-decision"><day>17</day><month>12</month><year>2021</year></date><date date-type="corrected-typeset"><day>31</day><month>1</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>12</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>01</day><month>02</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-02-03 16:16:38.487"><day>03</day><month>02</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ofab649.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ofab649.pdf"/><abstract><title>Abstract</title><sec id="s100"><title>Background</title><p>The relative distribution of cefazolin into the cerebrospinal fluid (CSF) remains debated. Determining the distribution of cefazolin into the CSF in noninfected adults may allow for further treatment applications of cefazolin. This prospective pharmacokinetic study aimed to determine the pharmacokinetic parameters of cefazolin in serum and CSF from external ventricular drains (EVDs) in neurologically injured adults.</p></sec><sec id="s101"><title>Methods</title><p>Blood and CSF were collected, using a biologic waste protocol, for cefazolin quantification and trapezoidal rule&#8211;based pharmacokinetic analysis in a total of 15 critically ill adults receiving 2000&#160;mg intravenously every 8 hours or the renal dose equivalent for EVD prophylaxis.</p></sec><sec id="s102"><title>Results</title><p>A median (range) of 3 (2&#8211;4) blood and 3 (2&#8211;5) CSF samples were collected for each patient. The most common admitting diagnosis was subarachnoid hemorrhage (66.7%). The median calculated cefazolin CSF C<sub>max</sub> and C<sub>min</sub> values (interquartile range [IQR]) were 2.97 (1.76&#8211;8.56) mg/L and 1.59 (0.77&#8211;2.17) mg/L, respectively. The median (IQR) CSF to serum area under the curve ratio was 6.7% (3.7%&#8211;10.6%), with time-matched estimates providing a similar estimate (8.4%). Of those receiving cefazolin every 8 hours, the median and minimum directly measured CSF cefazolin concentration &#8805;4 hours following administration were 1.87 and 0.78&#160;mg/L, respectively.</p></sec><sec id="s103"><title>Conclusions</title><p>Cefazolin dosed for EVD prophylaxis achieved CSF concentrations suggesting viability as a therapeutic option for patients with meningitis or ventriculitis due to susceptible bacteria such as methicillin-susceptible <italic toggle="yes">Staphylococcus aureus</italic>. Further clinical trials are required to confirm a role in therapy for cefazolin. Population-based pharmacokinetic&#8211;pharmacodynamic modeling may suggest an optimal cefazolin regimen for the treatment of central nervous system infections.</p></sec></abstract><abstract abstract-type="teaser"><p>D/C/F/TAF is the reference for combination therapy based on protease inhibitors but has not been compared with regimens containing integrase inhibitors as initial ART. We could not demonstrate D/C/F/TAF noninferiority relative to DTG/ABC/3TC, although both regimens were similarly well tolerated.</p></abstract><kwd-group><kwd>cefazolin</kwd><kwd>cerebrospinal fluid</kwd><kwd>cerebrospinal fluid shunts</kwd><kwd>critical care</kwd><kwd>critical illness</kwd><kwd>distribution</kwd><kwd>pharmacokinetics</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>University of Colorado Skaggs School of Pharmacy</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Department of Clinical Pharmacy and the Associate Dean of Research</institution></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="6"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The current Infectious Disease Society of America recommendation for the treatment of meningitis or ventriculitis due to methicillin-susceptible <italic toggle="yes">Staphylococcus</italic> spp., including <italic toggle="yes">S. aureus</italic> (MSSA), is intravenous nafcillin or oxacillin, with the provisional addition of rifampin in cases involving foreign bodies (eg, shunts) [<xref rid="CIT0001" ref-type="bibr">1</xref>, <xref rid="CIT0002" ref-type="bibr">2</xref>]. The cerebrospinal fluid (CSF) and brain tissue penetration estimates of specific antistaphylococcal &#946;-lactams have remained an area of debate for decades [<xref rid="CIT0003" ref-type="bibr">3&#8211;8</xref>]. Recent studies have suggested that cefazolin is as effective as, potentially better tolerated than, and has a more favorable dosing schedule than antistaphylococcal penicillins for the treatment MSSA infections from non-CSF sources [<xref rid="CIT0009" ref-type="bibr">9</xref>, <xref rid="CIT0010" ref-type="bibr">10</xref>]. The absence of cefazolin as a treatment option for highly susceptible isolates in CSF is due to a lack of clinical evidence and a presumed inability to achieve therapeutic CSF concentrations at conventional doses. In part, this is due to relatively high protein binding compared with most cephalosporins, low lipophilicity, and affinity for blood&#8211;brain barrier efflux pumps [<xref rid="CIT0011" ref-type="bibr">11</xref>].</p><p>Many of the original studies describing the limited central nervous system (CNS) penetration of cefazolin were based on single-dose pharmacokinetics and not entirely reflective of clinical practice and individual patient characteristics [<xref rid="CIT0011" ref-type="bibr">11&#8211;13</xref>]. Animal and limited human reports indicate that there may be CNS penetration of cefazolin at therapeutically used doses [<xref rid="CIT0012" ref-type="bibr">12</xref>, <xref rid="CIT0014" ref-type="bibr">14</xref>]. Further, a recent case report and case series suggested that continuous infusion of cefazolin can achieve therapeutic CSF concentrations resulting in bacterial eradication with the aid of therapeutic drug monitoring (TDM) [<xref rid="CIT0006" ref-type="bibr">6</xref>, <xref rid="CIT0007" ref-type="bibr">7</xref>]. If cefazolin adequately penetrates into the CSF and clinical trials confirm safety and efficacy for targeted susceptible central nervous system infections, clinicians would be presented with another treatment option.</p><p>The purpose of this study was to describe the pharmacokinetic (PK) parameters of cefazolin in CSF and serum in noninfected adults with actively draining external ventricular drains (EVDs). By determining the distribution and PK profile of cefazolin in CSF at approved and commonly used doses, further treatment applications of cefazolin for infections involving the central nervous system and regimen optimization may be determined.</p><sec sec-type="materials" id="s1"><title>METHODS</title><sec id="s2"><title>Setting/Patient Consent</title><p>This single-center, prospective observational PK analysis was conducted at UCHealth, a 662-bed academic medical center. The Colorado Multiple Institutional Review Board reviewed the study (COMIRB 19&#8208;2069) and waived the requirement of consent under a biological waste secondary use collection protocol, which allowed for secondary deidentified analysis of data once collected and analysis of biological samples once they were deemed waste.</p></sec><sec id="s3"><title>Population</title><p>Hospitalized patients&#8197;<italic toggle="yes">&gt;</italic>18 years of age who had a non-antibiotic-coated EVD open to drain, who were receiving cefazolin for EVD prophylaxis and had&#8197;&#8805;2 planned clinical laboratory tests ordered requiring blood draws within a cefazolin dosing interval, were eligible for inclusion.</p></sec><sec id="s4"><title>Sample Collection</title><p>The blood samples were obtained from the clinical laboratory after the clinically indicated tests were completed as permitted under the biological waste protocol. Samples were obtained at multiple time points within the dosing interval for analysis. As waste samples were generated as part of routine care, blood sample timing in relation to cefazolin administration was variable and not controlled by investigators. Biological waste blood was handled under a routine protocol at the clinical laboratory until it was released to an investigator for processing and storage.</p><p>The CSF samples were taken from actively draining EVDs just before collecting bags and volumes recorded as to not interfere with routine care and documentation of total CSF drain volume. CSF drainage was considered waste if the attending physician determined that no clinical use would be expected except for the documentation of volume, which was not interrupted. Typically, 1&#8211;3&#160;mL of CSF was collected at various time points that attempted to match the timing of clinical lab blood draws in the anticipation of recovering waste blood from the clinical laboratory. It was anticipated that patients would rarely be identified and assessed during the first dose upon admission to the neurosurgical intensive care unit or perioperatively; therefore, no first-dose cefazolin intervals were pursued. At our institution, it was common practice for patients to receive systemic cefazolin for EVD infection prophylaxis when antimicrobial-impregnated drains were not utilized. All collected samples were analyzed for cefazolin and used for PK analysis. All the samples were centrifuged at 2500&#160;rpm for 20 minutes, supernatant-pipetted, and stored at &#8211;80&#176;C in triplicate in 0.3&#8211;1-mL microcentrifuge tubes until assay.</p></sec><sec id="s5"><title>Data Collection</title><p>Patients included in the data analysis were evaluated manually by a single study investigator to assess eligibility based on previously described inclusion and exclusion criteria. Demographic and outcome data for all patients were then extracted via manual chart review from the electronic medical record.</p></sec><sec id="s6"><title>Sample Analysis and Materials</title><p>Cefazolin was quantified, after protein precipitation, by a high-performance liquid chromatography&#8211;tandem mass spectrometry method developed by iC42 Clinical Research and Development (University of Colorado Anschutz Medical Campus, Aurora, CO, USA; bioanalytics.us). In brief, analytical grade cefazolin (C242500; Lot #25-SSR 120-1) and internal standard N15,2C13-Cefazolin (C242502; Lot #8-XAL 141010) were purchased from Toronto Research Chemicals (North York, ON, Canada). A cefazolin standard curve was constructed in both serum and CSF using a quadratic fit after 1/x weighting. Cefazolin concentrations were quantitated by plotting analyte peak area/internal standard peak ratios against the standard curve. All calculations were carried out using AB Sciex Analyst software (version 1.6.2). The lower limit of quantification was 0.025&#160;mg/L, and calibration curves had a coefficient of determination&#8197;&gt;0.99. Intrabatch accuracy during analysis was between 85% and 115%, with a coefficient of variance&#8197;&#8804;15%. Blank/zeroed samples showed no significant interference.</p></sec><sec id="s7"><title>Statistical Analysis</title><p>Descriptive statistics were used to describe the population. Cefazolin PK were generated using 1-compartment estimations for serum by plotting concentrations and time of documented clinical blood draw relative to the documented cefazolin dose. A log linear best fit trapezoidal rule was used to estimate the elimination rate, peak (C<sub>max</sub>), trough (C<sub>min</sub>), and area under the curve (AUC) values for the dosing interval. Although limited, this method was used to generate similar estimates for CSF concentrations. Estimated AUC<sub>CSF</sub>:AUC<sub>Serum</sub> within the same interval was used to estimate the CSF distribution. Time-matched concentrations were analyzed in a point-by-point CSF:serum concentration ratio to provide a secondary measurement of CSF distribution. In this ratio, CSF samples collected 1&#8211;180 minutes following a recovered blood draw, for clinical purposes, were used to provide a reasonable second estimate of cefazolin CSF penetration.</p></sec></sec><sec id="s8"><title>RESULTS</title><p>A total of 15 patients (80% female) were included in the study, with a respective median age, weight, body mass index, and creatinine clearance of 56 years, 71.7&#160;kg, 26.3&#160;kg/m<sup>2</sup>, and 115&#160;mL/min. The baseline demographics of patients are presented in <xref rid="T1" ref-type="table">Table 1</xref>. All but 1 patient had an EVD placed subsequent to an intracranial hemorrhage, and 66.7% involved a subarachnoid hemorrhage. One patient had an EVD placed following a brain tumor resection for intracranial pressure relief. The median (interquartile range [IQR]) daily EVD output on the day of CSF sampling was 126 (89&#8211;186) mL. All patients were prescribed cefazolin intravenously (IV) for EVD prophylaxis without suspected infection adjusted for renal function at 2000&#160;mg IV every 8 hours (n&#8197;=&#8197;13), 2000&#160;mg IV every 12 hours (n&#8197;=&#8197;1), and 500&#160;mg IV every 24 hours (n&#8197;=&#8197;1). A total of 39 serum samples and 44 CSF samples were obtained, with a median of 3 each per sample per patient, at a median (IQR) of 2.5 (1.5&#8211;7) days from first cefazolin dose. No samples were obtained following the first cefazolin dose or on the first calendar day of cefazolin initiation. One patient receiving 2000&#160;mg IV every 8 hours did not have at least 2 serum samples recoverable within the same dosing interval; therefore, systemic AUC and AUC<sub>CSF</sub>:AUC<sub>Serum</sub> estimation was not calculated. For this patient, 3 CSF samples within a dosing interval were analyzed and reported, and 1 CSF sample was timed to a matched serum concentration for point-by-point analysis.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p>Patient Demographics</p></caption><table frame="hsides" rules="groups" width="100%" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Characteristic </th><th align="center" rowspan="1" colspan="1">All Patients (n&#8197;=&#8197;15) </th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"> Female sex</td><td align="center" rowspan="1" colspan="1">12 (80)</td></tr><tr><td align="center" rowspan="1" colspan="1"> Age, y</td><td align="center" rowspan="1" colspan="1">56 (51&#8211;60)</td></tr><tr><td align="center" rowspan="1" colspan="1"> Height, cm</td><td align="center" rowspan="1" colspan="1">167.6 (163.9&#8211;172.7)</td></tr><tr><td align="center" rowspan="1" colspan="1"> Weight, kg</td><td align="center" rowspan="1" colspan="1">71.7 (65&#8211;89)</td></tr><tr><td align="center" colspan="2" rowspan="1"> Race/ethnicity</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;White</td><td align="center" rowspan="1" colspan="1">10 (66.7)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Black or African American</td><td align="center" rowspan="1" colspan="1">2 (13.3)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Other</td><td align="center" rowspan="1" colspan="1">3 (20.0)</td></tr><tr><td align="center" rowspan="1" colspan="1">Creatinine clearance, mL/min<xref rid="T1Fn3" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" rowspan="1" colspan="1">115 (84&#8211;174)</td></tr><tr><td align="center" colspan="2" rowspan="1">Creatinine clearance, cefazolin dose, and interval</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;<italic toggle="yes">&gt;</italic>50&#160;mL/min, 2000&#160;mg every 8 h</td><td align="center" rowspan="1" colspan="1">13 (86.7)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;11&#8211;49&#160;mL/min, 2000&#160;mg every 12 h</td><td align="center" rowspan="1" colspan="1">1 (6.7)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;<italic toggle="yes">&lt;</italic>10&#160;mL/min, 500&#160;mg every 24 h</td><td align="center" rowspan="1" colspan="1">1 (6.7)</td></tr><tr><td align="center" colspan="2" rowspan="1"> EVD placement</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Left frontal</td><td align="center" rowspan="1" colspan="1">2 (13.3)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Right frontal</td><td align="center" rowspan="1" colspan="1">11 (73.3)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Other</td><td align="center" rowspan="1" colspan="1">2 (13.3)</td></tr><tr><td align="center" colspan="2" rowspan="1"> Admission diagnosis<xref rid="T1Fn4" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Subarachnoid hemorrhage</td><td align="center" rowspan="1" colspan="1">10 (66.7)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Intraparenchymal hemorrhage</td><td align="center" rowspan="1" colspan="1">4 (26.7)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Intraventricular hemorrhage</td><td align="center" rowspan="1" colspan="1">4 (26.7)</td></tr><tr><td align="center" rowspan="1" colspan="1"> EVD output in 24&#160;h, mL</td><td align="center" rowspan="1" colspan="1">126 (89&#8211;186)</td></tr></tbody></table><table-wrap-foot><fn id="T1Fn1"><p>Data reported as No. (%) or median (interquartile range).</p></fn><fn id="T1Fn2"><p>Abbreviation: EVD, external ventricular drain.</p></fn><fn id="T1Fn3"><p>Calculated via Cockcroft-Gault equation.</p></fn><fn id="T1Fn4"><p>Some patients had multiple hemorrhage locations/diagnoses.</p></fn></table-wrap-foot></table-wrap><p>Estimated PK parameters for cefazolin serum and CSF concentrations are presented in <xref rid="T2" ref-type="table">Table 2</xref>. All CSF samples were within the limit of assay quantification developed at the iC42 laboratory, with a directly measured median (IQR) concentration of 1.99 (1.28&#8211;3.14) mg/L. The maximum and minimum directly measured CSF concentrations were 11.5&#160;mg/L and 0.78&#160;mg/L, respectively. Cohort-extrapolated median (IQR) C<sub>max</sub> and C<sub>min</sub> concentrations were 2.97 (1.76&#8211;8.56) mg/L and 1.59 (0.77&#8211;2.17) mg/L, respectively. Within the 2000&#160;mg IV every 8 hours group, 16 CSF samples were obtained &gt;4 hours after infusion, with a median and minimum directly measured concentration of 1.87 and 0.78&#160;mg/L. The median (IQR) distribution ratios of CSF to serum by estimated AUC<sub>interval</sub> was 6.7% (3.9%&#8211;11.3%). A total of 29 CSF samples were obtained within 1&#8211;180 minutes after a recovered blood sample for a time-matched CSF distribution analysis. The median (IQR) CSF:serum ratio in matched times was 8.4% (5%&#8211;11%). We did not observe a relationship between time from first cefazolin dose to sample obtainment and CSF:serum ratio for AUC analysis or average point-by-point analysis (<italic toggle="yes">R</italic><sup>2</sup>&#8197;=&#8197;0.0004 and 0.095, respectively).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><p>Pharmacokinetics for Both Serum and Cerebrospinal Fluid</p></caption><table frame="hsides" rules="groups" width="100%" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Variable </th><th align="center" rowspan="1" colspan="1">All Patients </th><th align="center" rowspan="1" colspan="1">Creatinine Clearance&#8197;&gt;50&#160;mL/min </th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Interval dose, mg</td><td align="center" rowspan="1" colspan="1">Variable</td><td align="center" rowspan="1" colspan="1">2000</td></tr><tr><td align="center" colspan="3" rowspan="1">Serum pharmacokinetic parameters</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;No. of patients</td><td align="center" rowspan="1" colspan="1">14<xref rid="T2Fn3" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" rowspan="1" colspan="1">12<xref rid="T2Fn3" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;C<sub>max</sub>, mg/L</td><td align="center" rowspan="1" colspan="1">77.6 (54.4&#8211;176.2)</td><td align="center" rowspan="1" colspan="1">75.9 (52.7&#8211;90.3)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;C<sub>min</sub>, mg/L</td><td align="center" rowspan="1" colspan="1">10.8 (8.3&#8211;27.2)</td><td align="center" rowspan="1" colspan="1">10.2 (8.1&#8211;24.2)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Elimination constant, h<sup>-1</sup></td><td align="center" rowspan="1" colspan="1">0.21 (0.13&#8211;0.27)</td><td align="center" rowspan="1" colspan="1">0.22 (0.14&#8211;0.28)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Half-life, h</td><td align="center" rowspan="1" colspan="1">3.37 (2.6&#8211;5.4)</td><td align="center" rowspan="1" colspan="1">3.18 (2.5&#8211;4.9)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Clearance, L/h</td><td align="center" rowspan="1" colspan="1">6.61 (4.1&#8211;9.7)</td><td align="center" rowspan="1" colspan="1">7.48 (5.4&#8211;9.9)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Volume of distribution, L</td><td align="center" rowspan="1" colspan="1">31.42 (13.8&#8211;49.8)</td><td align="center" rowspan="1" colspan="1">33.39 (23.9&#8211;61.6)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Weight adjusted volume of distribution, L/kg</td><td align="center" rowspan="1" colspan="1">0.42 (0.19&#8211;0.74)</td><td align="center" rowspan="1" colspan="1">0.56 (0.29&#8211;0.83)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;AUC<sub>dosing interval</sub>, mg<sup>&#8727;</sup>h/L</td><td align="center" rowspan="1" colspan="1">302.4 (206&#8211;501)</td><td align="center" rowspan="1" colspan="1">270.6 (201&#8211;372)</td></tr><tr><td align="center" colspan="3" rowspan="1">CSF pharmacokinetic parameters</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;No. of patients</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;C<sub>max</sub>, mg/L</td><td align="center" rowspan="1" colspan="1">2.97 (1.6&#8211;11)</td><td align="center" rowspan="1" colspan="1">2.88(1.4&#8211;5.2)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;C<sub>min</sub>, mg/L</td><td align="center" rowspan="1" colspan="1">1.59 (0.7&#8211;2.2)</td><td align="center" rowspan="1" colspan="1">1.07 (0.6&#8211;2.2)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;CSF elimination constant, h<sup>-1</sup></td><td align="center" rowspan="1" colspan="1">0.11 (0.05&#8211;0.13)</td><td align="center" rowspan="1" colspan="1">0.08 (0.05&#8211;0.12)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;CSF half-life, h</td><td align="center" rowspan="1" colspan="1">6.46 (5.5&#8211;13.1)</td><td align="center" rowspan="1" colspan="1">8.39 (5.7&#8211;13.7)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;CSF AUC<sub>dosing interval</sub>, mg<sup>&#8727;</sup>h/L</td><td align="center" rowspan="1" colspan="1">18.19 (10&#8211;32)</td><td align="center" rowspan="1" colspan="1">15.95 (9&#8211;28)</td></tr><tr><td align="center" colspan="3" rowspan="1">CSF:serum estimated ratios</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;CSF:serum AUC ratio,<xref rid="T2Fn3" ref-type="table-fn"><sup>a</sup></xref> %</td><td align="center" rowspan="1" colspan="1">6.7 (3.9&#8211;11.3)<xref rid="T2Fn3" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" rowspan="1" colspan="1">4.1 (3.8&#8211;12.9)<xref rid="T2Fn3" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;CSF:serum time matched ratio, %</td><td align="center" rowspan="1" colspan="1">8.4 (5&#8211;11)</td><td align="center" rowspan="1" colspan="1">8.3 (4.8&#8211;11.2)</td></tr></tbody></table><table-wrap-foot><fn id="T2Fn1"><p>Data are reported as No. (%) or median (interquartile range).</p></fn><fn id="T2Fn2"><p>Abbreviations: AUC, estimated area under the curve; C<sub>max</sub>, extrapolated maximum concentration; C<sub>min</sub>, extrapolated minimum concentration; CSF, cerebrospinal fluid.</p></fn><fn id="T2Fn3"><p>One patient was excluded from serum pharmacokinetic evaluation as multiple blood samples from a dosing interval were not recovered, n&#8197;=&#8197;14 for all and n&#8197;=&#8197;12 for creatinine clearance&#8197;&gt;50&#160;mL/min.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s9"><title>DISCUSSION</title><p>In this prospective cohort of neurosurgical patients with EVDs receiving cefazolin for prophylaxis, we observed variable yet reasonable CSF distribution at commonly used doses. Cefazolin is an effective agent for many susceptible gram-positive and gram-negative bacterial infections. It is likely as effective as and possibly better tolerated than antistaphylococcal penicillins for most infections due to MSSA [<xref rid="CIT0009" ref-type="bibr">9</xref>, <xref rid="CIT0010" ref-type="bibr">10</xref>, <xref rid="CIT0015" ref-type="bibr">15&#8211;17</xref>]. Our analysis provides important estimates of cefazolin CSF concentrations in a cohort of noninfected patients. These estimates may be useful in the design of therapeutic studies evaluating cefazolin for infections involving the central nervous system while minimizing the risk of cefazolin-related neurotoxicity.</p><p>The ability of cefazolin to reach therapeutic CSF concentrations has been debated. Historically, cefazolin not been recommended for the majority of infections involving the CNS [<xref rid="CIT0001" ref-type="bibr">1</xref>, <xref rid="CIT0002" ref-type="bibr">2</xref>]. Early studies reported undetectable cefazolin CSF concentrations after a single 1000-mg dose but brain tissue concentrations of 2&#8211;40 mcg/g after a single 2000-mg dose [<xref rid="CIT0003" ref-type="bibr">3</xref>, <xref rid="CIT0004" ref-type="bibr">4</xref>]. Conversely, significant CSF accumulation and neurotoxicity were reported by others after multiple doses [<xref rid="CIT0012" ref-type="bibr">12</xref>]. More recently, potentially therapeutic concentrations of cefazolin in CSF samples have been reported in less well-defined or smaller populations, though some reports rely on the low MSSA minimum inhibitory concentration (MIC) of 0.5&#160;mg/L, which is an important caveat [<xref rid="CIT0006" ref-type="bibr">6</xref>, <xref rid="CIT0007" ref-type="bibr">7</xref>, <xref rid="CIT0018" ref-type="bibr">18</xref>, <xref rid="CIT0019" ref-type="bibr">19</xref>]. Of interest, 1 report used serial therapeutic drug monitoring and continuous infusion cefazolin of 10 or 8&#160;g daily to effectively treat MSSA ventriculitis [<xref rid="CIT0006" ref-type="bibr">6</xref>]. This case report found a median CSF concentration of 12&#160;mg/L with a CSF:plasma ratio of 12% during a 10-g/d continuous infusion and a median CSF concentration of 6.1&#160;mg/L with a CSF:plasma ratio of 10% during an 8-g/d continuous infusion. These investigators conducted a retrospective analysis of patients treated with cefazolin continuous infusion and CSF therapeutic drug monitoring for staphylococcal meningitis. In 14 CSF samples analyzed in 8 patients treated with a median (range) continuous infusion of 8 (6&#8211;12) g/d, they reported a median (IQR) cefazolin concentration of 2.8 (2.1&#8211;5.2) mg/L and a corresponding CSF:plasma ratio of 4.3% (2.9%&#8211;8.4%). In 4 patients without meningitis, these investigators observed lower median CSF concentrations and distribution ratios of 0.95 (0.5&#8211;1.4) mg/L and 2.1% (0.9%&#8211;5.2%), respectively [<xref rid="CIT0007" ref-type="bibr">7</xref>]. Although intriguing, the safety of higher total daily doses of cefazolin remains to be established. Our data concur with these reports, providing an estimate of CSF distribution that is within the variations reported by that study group [<xref rid="CIT0006" ref-type="bibr">6</xref>, <xref rid="CIT0007" ref-type="bibr">7</xref>]. These differences may be explained by dosing strategies and patient-specific factors. As an observational study, we assessed standard intermittent doses of cefazolin adjusted for renal function, not high-dose continuous infusion. It is possible that greater drug and dose exposure led to an increased CSF distribution ratio. This may explain a ratio decrease from 12% to 10% in the same patient after the dose was decreased secondary to therapeutic drug monitoring in plasma and CSF in the case report [<xref rid="CIT0006" ref-type="bibr">6</xref>]. Additionally, we assessed CSF distribution in EVD output during prophylaxis and not in patients suspected to have ventriculitis. The additional inflammation occurring from ventriculitis would be expected to increase blood&#8211;brain barrier permeability perhaps beyond that of EVD placement alone. In the retrospective study, CSF inflammation was likely a factor in lower CSF distribution ratios, as reported in those without meningitis [<xref rid="CIT0007" ref-type="bibr">7</xref>]. Regardless, our estimates of CSF distribution, combined with recently published reports, provide independent evidence that cefazolin can reach therapeutic concentrations in the CSF. Although the CSF distribution ratio may be variable, it is likely within the estimate ranges discussed above.</p><p>The Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) eliminated cefazolin interpretive breakpoints for <italic toggle="yes">S. aureus</italic> [<xref rid="CIT0020" ref-type="bibr">20</xref>]. However, the EUCAST MICs<sub>50/90</sub> for MSSA are 0.5 and 1&#160;mg/L, respectively, with an epidemiologic cutoff of 2&#160;mg/L [<xref rid="CIT0021" ref-type="bibr">21</xref>]. Although a CSF pharmacodynamic (PD) target for meningitis or ventriculitis has not been established, our study and previous reports suggest that cefazolin is viable to meet commonly used PD targets of time above MIC&#8197;&gt;35% or 100% for MIC<sub>50/90</sub> values. Nevertheless, caution is warranted, as the lower quartile estimated trough in our standard dosing cohort was &lt;1&#160;mg/L. Similarly, it is unlikely that standard cefazolin doses would meet PD targets for pathogens with higher MICs, and alternative dosing strategies or agents should be considered. Determining the pathogen MIC for an antibiotic of interest, as is the case for <italic toggle="yes">Streptococcus pneumoniae</italic> meningitis, before instituting targeted definitive therapy remains prudent. If possible, therapeutic drug monitoring could provide additional information regarding drug penetration at the site of infection, allowing for alternative dosing strategies to optimize efficacy while minimizing overexposure. This strategy has been reported for other &#946;-lactams beyond the therapeutic drug monitoring of cefazolin [<xref rid="CIT0007" ref-type="bibr">7</xref>, <xref rid="CIT0018" ref-type="bibr">18</xref>]. Importantly cefazolin, among other antibiotics, has been reported to have increased MICs in the presence of a large number of organisms (MSSA in particular), occasionally leading to clinical failure in deep-seated infections [<xref rid="CIT0022" ref-type="bibr">22</xref>, <xref rid="CIT0023" ref-type="bibr">23</xref>]. This phenomenon, coined the cefazolin inoculum effect (CIE), is a result of MSSA producing &#946;-lactamases encoded by the blaZ gene [<xref rid="CIT0024" ref-type="bibr">24</xref>, <xref rid="CIT0025" ref-type="bibr">25</xref>]. The clinical significance of the CIE is not entirely clear, as while some studies show higher rates of clinical failure and mortality in the presence of the CIE, other studies do not show poorer outcomes with cefazolin as compared with antistaphylococcal penicillins. In certain conditions, potential complications with high bacterial burden may be mitigated by appropriate source control [<xref rid="CIT0016" ref-type="bibr">16</xref>, <xref rid="CIT0020" ref-type="bibr">20</xref>]. Source control in the CNS would include infected device removal and prompt abscess drainage of any formed abscess.</p><p>Comparatively, other antistaphylococcal penicillins have variable CSF penetration, in some cases less than that of cefazolin. Le Turnier et al. reported lower median (IQR) CSF:plasma ratios and steady state CSF concentrations of 1.8% (1.7%&#8211;2.8%) and 0.66 (0.5&#8211;0.9) mg/L, respectively, with cloxacillin 12&#160;g IV daily compared with cefazolin [<xref rid="CIT0007" ref-type="bibr">7</xref>]. A 3% ratio of CSF:unbound plasma concentration for cloxacillin has been estimated by others [<xref rid="CIT0026" ref-type="bibr">26</xref>]. Flucloxacillin 2000&#160;mg IV every 4 hours resulted in CSF concentrations of 0.3&#160;mg/L, and others report very low CSF concentrations even when utilizing continuous infusions [<xref rid="CIT0027" ref-type="bibr">27</xref>]. Conversely, nafcillin CSF concentrations are reported as adequate to treat MSSA CSF infections. Daily nafcillin doses of 100&#8211;200&#160;mg/kg resulted in adequate CSF concentrations for MSSA [<xref rid="CIT0028" ref-type="bibr">28</xref>]. However, a single nafcillin dose of 40&#160;mg/kg IV in 8 patients resulted in a mean CSF concentration of 0.12&#160;mg/L at 2 hours postdose and a mean CSF concentration of 0.03&#160;mg/L at 4 hours postdose in patients with no meningeal inflammation [<xref rid="CIT0029" ref-type="bibr">29</xref>]. In 7 patients with bacterial ventriculitis, CSF nafcillin was reported as 0.8%&#8211;20.4% peak serum concentrations [<xref rid="CIT0030" ref-type="bibr">30</xref>]. Brain tissue concentrations following 2000&#160;mg IV of nafcillin in 13 patients resulted in a mean of 2.7 mcg/g, whereas cefazolin 2000&#160;mg IV resulted a mean of 10.6 mcg/g, suggesting comparable brain penetration of both nafcillin and cefazolin [<xref rid="CIT0004" ref-type="bibr">4</xref>].</p><p>This study has several important limitations. We assessed cefazolin distribution using 2 methods through a biological waste secondary use protocol. As such, these values should be viewed as estimates, as a formal PK study was not possible and somewhat unsophisticated single-compartment trapezoidal calculations were used to provide estimates, which did not account for delayed CSF distribution. However, both AUC<sub>CSF</sub>:AUC<sub>Serum</sub> and matched point estimates resulted in serum to CSF distribution concordant values in line with previous reports. Nevertheless, significant variability around CSF penetration exists within our cohort of patients. This variability has also been reported by others, suggesting an IQR spread similar to the estimated median CSF percent distribution ratio [<xref rid="CIT0007" ref-type="bibr">7</xref>]. This observation is also true of extrapolated CSF C<sub>min</sub> values and was of concern in our cohort as values approached commonly reported MICs of targeted pathogens when 2&#160;g IV every 8 hours dosing (with renal adjustment) was used. In the 16 CSF samples obtained &gt;4 hours after infusion with a median and minimum directly measured concentration of 1.87 and 0.78&#160;mg/L, we are reminded that an appropriate dosing schedule selection is critical, especially in individuals with potential augmented renal clearance and/or individuals at high risk for treatment failure due to high-inoculum MSSA infection or retained hardware. Given the free drug time above MIC PD target of cefazolin, alternative dosing strategies such as more frequent dosing, extended interval dosing, or continuous infusion, especially in those with high renal clearance, may be required to optimize efficacy and safety. Future PK/PD modeling beyond the limited trapezoidal estimates in the CSF compartment and clinical studies is required to provide more insight into optimized dosing strategies, target CSF concentrations, and the overall efficacy and safety of cefazolin as a targeted therapy compared with standard of care before use can be widely adopted. In addition, we did not assess meningeal inflammation in our cohort. Our patients were not suspected to have meningitis or ventriculitis, which may increase blood&#8211;brain barrier permeability. Although the insertion of an EVD is traumatic and our population had underlying reasons for meningeal inflammation, we cannot comment on the relative difference in inflammation and drug distribution expected in those with meningitis. Lastly, CSF samples were obtained from a single EVD after a median of 2.5 days from cefazolin initiation. These estimates assume both steady state in CSF distribution and homogenous mixing between EVD output and the CSF compartment.</p></sec><sec id="s10"><title>CONCLUSIONS</title><p>In a prospective cohort of 15 critically ill neurosurgical patients with EVDs, we observed variable cefazolin CSF concentrations and relative CSF distribution. These estimates suggest that cefazolin may be a viable option for the treatment of meningitis or ventriculitis due to susceptible bacteria. Optimal dosing regimens for this indication require further study and may be aided by therapeutic drug monitoring. Ultimately, clinical studies evaluating the efficacy and safety of cefazolin, with or without additional antimicrobials, are needed to define a role in therapy.</p></sec></body><back><ack id="a1"><title>Acknowledgments</title><p>We acknowledge Deborah Sherman, PharmD, for assistance in identifying patients and the Neurosurgical Interdisciplinary Team (MDs, RNs, and Advanced Practitioners) for assistance with biological waste sample collection.</p><p>
<bold>
<italic toggle="yes">Financial support.</italic>
</bold> This work was partially supported by seed grants from University of Colorado Skaggs School of Pharmacy, Department of Clinical Pharmacy and the Associate Dean of Research (S.W.M.). </p><p>
<bold>
<italic toggle="yes">Potential conflicts of interest.</italic>
</bold> All investigators are supported by the National Institutes of Health (NIH)/National Center for Advancing Translation Sciences (NCATS) Colorado CTSA (Grant Number UL1 TR002535). The authors declare no other disclosures or conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</p><p>
<bold>
<italic toggle="yes">Author contributions.</italic>
</bold> M.K., R.T.N., L.C.P., K.C.M., S.W.M. designed the study; A.R.N., S.W.M. collected patient samples; A.R.N., T.H.K., K.C.M., S.W.M. pharmacokinetic analysis and statistics; M.K. and S.W.M. obtained seed funding; A.R.N., M.K., T.H.K., R.T.N., L.C.P., K.C.M., S.W.M. prepared and made substantial comments to the manuscript.</p></ack><ref-list id="r1"><title>References</title><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tunkel</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Hasbun</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bhimraj</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Infectious Diseases Society of America&#8217;s clinical practice guidelines for healthcare-associated ventriculitis and meningitis.</article-title><source>Clin Infect Dis</source><year>2017</year>; <volume>64</volume>:<fpage>e34</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">28203777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciw861</pub-id><pub-id pub-id-type="pmcid">PMC5848239</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tunkel</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Hartman</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Kaplan</surname><given-names>SL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Practice guidelines for the management of bacterial meningitis.</article-title><source>Clin Infect Dis</source><year>2004</year>; <volume>39</volume>:<fpage>1267</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">15494903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/425368</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bassaris</surname><given-names>HP</given-names></string-name>, <string-name name-style="western"><surname>Quintiliani</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Maderazo</surname><given-names>EG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Pharmacokinetics and penetration characteristics of cefazolin into human spinal fluid.</article-title><source>Curr Ther Res Clin Exp</source><year>1976</year>; <volume>19</volume>:<fpage>110</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">812655</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frame</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Watanakunakorn</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>McLaurin</surname><given-names>RL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Penetration of nafcillin, methicillin, and cefazolin into human brain tissue.</article-title><source>Neurosurgery</source><year>1983</year>; <volume>12</volume>:<fpage>142</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">6835496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1227/00006123-198302000-00002</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thys</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Vanderkelen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Klastersky</surname><given-names>J.</given-names></string-name></person-group><article-title>Pharmacological study of cefazolin during intermittent and continuous infusion: a crossover investigation in humans.</article-title><source>Antimicrob Agents Chemother</source><year>1976</year>; <volume>10</volume>:<fpage>395</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">984782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.10.3.395</pub-id><pub-id pub-id-type="pmcid">PMC429759</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gr&#233;goire</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gaborit</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Deschanvres</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>High-dosage cefazolin achieves sufficient cerebrospinal diffusion to treat an external ventricular drainage-related staphylococcus aureus ventriculitis.</article-title><source>Antimicrob Agents Chemother</source><year>2019</year>; <volume>63</volume>:<fpage>e01844-18</fpage>.<pub-id pub-id-type="pmid">30420481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01844-18</pub-id><pub-id pub-id-type="pmcid">PMC6355608</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Le Turnier</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gr&#233;goire</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Deslandes</surname><given-names>G</given-names></string-name>, <etal>et al;</etal></person-group><person-group><collab>NAMPA study group.</collab></person-group><article-title>Should we reconsider cefazolin for treating staphylococcal meningitis? A retrospective analysis of cefazolin and cloxacillin cerebrospinal fluid levels in patients treated for staphylococcal meningitis.</article-title><source>Clin Microbiol Infect</source><year>2020</year>; <volume>26</volume>:<fpage>1415 e1</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">32437956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmi.2020.04.046</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chew</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Woods</surname><given-names>M.</given-names></string-name></person-group><article-title>Flucloxacillin does not achieve therapeutic cerebrospinal fluid levels against methicillin-sensitive <italic toggle="yes">Staphylococcus aureus</italic> in adults: a case report and review of the literature.</article-title><source>Int J Antimicrob Agents</source><year>2016</year>; <volume>47</volume>:<fpage>229</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">26915477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2015.12.009</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Miller</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Fish</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Barber</surname><given-names>GR</given-names></string-name>, <etal>et al.</etal></person-group><article-title>A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible <italic toggle="yes">Staphylococcus aureus</italic> bloodstream infections.</article-title><source>J Microbiol Immunol Infect</source><year>2020</year>; <volume>53</volume>:<fpage>321</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">30190234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmii.2018.07.006</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lecomte</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bourreau</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Deschanvres</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible <italic toggle="yes">Staphylococcus aureus</italic> infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study.</article-title><source>Clin Microbiol Infect</source><year>2021</year>; <volume>27</volume>:<fpage>1015&#8211;21</fpage>.<pub-id pub-id-type="pmid">32950711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmi.2020.08.044</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nau</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sorgel</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Eiffert</surname><given-names>H.</given-names></string-name></person-group><article-title>Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.</article-title><source>Clin Microbiol Rev</source><year>2010</year>; <volume>23</volume>:<fpage>858</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">20930076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00007-10</pub-id><pub-id pub-id-type="pmcid">PMC2952976</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moore</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Bechtel</surname><given-names>TP</given-names></string-name>, <string-name name-style="western"><surname>Ayers</surname><given-names>LW.</given-names></string-name></person-group><article-title>Effect of multidose therapy on cerebrospinal fluid penetration of cefazolin.</article-title><source>Am J Hosp Pharm</source><year>1981</year>; <volume>38</volume>:<fpage>1496</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">7294044</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cherubin</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Eng</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Norrby</surname><given-names>R</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Penetration of newer cephalosporins into cerebrospinal fluid.</article-title><source>Rev Infect Dis</source><year>1989</year>; <volume>11</volume>:<fpage>526</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">2672238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/clinids/11.4.526</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tsai</surname><given-names>TH</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YF.</given-names></string-name></person-group><article-title>Simultaneous determination of cefazolin in rat blood and brain by microdialysis and microbore liquid chromatography.</article-title><source>Biomed Chromatogr</source><year>2000</year>; <volume>14</volume>:<fpage>274</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">10861740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1099-0801(200006)14:4&lt;274::AID-BMC985&gt;3.0.CO;2-H</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Loubet</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Burdet</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Vindrios</surname><given-names>W</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible <italic toggle="yes">Staphylococcus aureus</italic> bacteraemia: a narrative review.</article-title><source>Clin Microbiol Infect</source><year>2018</year>; <volume>24</volume>:<fpage>125</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">28698037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmi.2017.07.003</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Echevarria</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Traugott</surname><given-names>KA.</given-names></string-name></person-group><article-title>Beta-Lactam therapy for methicillin-susceptible <italic toggle="yes">Staphylococcus aureus</italic> bacteremia: a comparative review of cefazolin versus antistaphylococcal penicillins.</article-title><source>Pharmacotherapy</source><year>2017</year>; <volume>37</volume>:<fpage>346</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">28035690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/phar.1892</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Allen</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Bakare</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Casapao</surname><given-names>AM</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with methicillin-susceptible <italic toggle="yes">Staphylococcus aureus</italic> infection: a meta-analysis with trial sequential analysis.</article-title><source>Infect Dis Ther</source><year>2019</year>; <volume>8</volume>:<fpage>671</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">31392580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40121-019-00259-4</pub-id><pub-id pub-id-type="pmcid">PMC6856230</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bellouard</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Deslandes</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Morival</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Simultaneous determination of eight beta-lactam antibiotics in human plasma and cerebrospinal fluid by liquid chromatography coupled to tandem mass spectrometry.</article-title><source>J Pharm Biomed Anal</source><year>2020</year>; <volume>178</volume>:<fpage>112904</fpage>.<pub-id pub-id-type="pmid">31606563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpba.2019.112904</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Klekner</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ga&#8217;spa&#8217;r</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kardos</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Cefazolin prophylaxis in neurosurgery monitored by capillary electrophoresis.</article-title><source>J Neurosurg Anesthesiol</source><year>2003</year>; <volume>15</volume>:<fpage>249</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">12826973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00008506-200307000-00013</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dein Bard</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hindler</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Gold</surname><given-names>HS</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Rationale for eliminating <italic toggle="yes">Staphylococcus</italic> breakpoints for &#946;-lactam agents other than penicillin, oxacillin or cefoxitin, and cefaroline.</article-title><source>Clin Infect Dis</source><year>2014</year>; <volume>58</volume>:<fpage>1287&#8211;96</fpage>.<pub-id pub-id-type="pmid">24457339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciu043</pub-id><pub-id pub-id-type="pmcid">PMC5734619</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21.</label><mixed-citation publication-type="other"><collab>European Committee on Antimicrobial Susceptibility Testing.</collab><comment>Data from the EUCAST MIC distribution website</comment>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://mic.eucast.org/search/?search%5Bmethod%5D=mic&amp;search%5Bantibiotic%5D=-1&amp;search%5Bspecies%5D=449&amp;search%5Bdisk_content%5D=-1&amp;search%5Blimit%5D=50" ext-link-type="uri">https://mic.eucast.org/search/?search%5Bmethod%5D=mic&amp;search%5Bantibiotic%5D=-1&amp;search%5Bspecies%5D=449&amp;search%5Bdisk_content%5D=-1&amp;search%5Blimit%5D=50</ext-link>. Accessed <comment>2 August 2021</comment>.</mixed-citation></ref><ref id="CIT0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lenhard</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Bulman</surname><given-names>ZP.</given-names></string-name></person-group><article-title>Inoculum effect of beta-lactam antibiotics.</article-title><source>J Antimicrob Chemother</source><year>2019</year>; <volume>74</volume>:<fpage>2825</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">31170287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkz226</pub-id><pub-id pub-id-type="pmcid">PMC6753498</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sabath</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Garner</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wilcox</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Effect of inoculum and of beta-lactamase on the anti-staphylococcal activity of thirteen penicillins and cephalosporins.</article-title><source>Antimicrob Agents Chemother</source><year>1975</year>; <volume>8</volume>:<fpage>344</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">1167043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.8.3.344</pub-id><pub-id pub-id-type="pmcid">PMC429316</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carvajal</surname><given-names>LP</given-names></string-name>, <string-name name-style="western"><surname>Rincon</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Echeverri</surname><given-names>AM</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Novel insights into the classification of staphylococcal beta-lactamases in relation to the cefazolin inoculum effect.</article-title><source>Antimicrob Agents Chemother</source>. <year>2020</year>; <volume>64</volume>:<fpage>e02511-19</fpage>.<pub-id pub-id-type="pmid">32071048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.02511-19</pub-id><pub-id pub-id-type="pmcid">PMC7179603</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rincon</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Carvajal</surname><given-names>LP</given-names></string-name>, <string-name name-style="western"><surname>Gomez-Villegas</surname><given-names>SI</given-names></string-name>, <etal>et al.</etal></person-group><article-title>A test for the rapid detection of the cefazolin inoculum effect in methicillin-susceptible <italic toggle="yes">Staphylococcus aureus</italic>.</article-title><source>J Clin Microbiol</source>. <year>2021</year>; <volume>59</volume>:<fpage>e01938-20</fpage>.<pub-id pub-id-type="pmid">33536292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JCM.01938-20</pub-id><pub-id pub-id-type="pmcid">PMC8092731</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schievink</surname><given-names>HI</given-names></string-name>, <string-name name-style="western"><surname>Mattie</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Thomeer</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The passage of cloxacillin into cerebrospinal fluid in the absence of meningitis.</article-title><source>Br J Clin Pharmacol</source><year>1993</year>; <volume>36</volume>:<fpage>57</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">8373712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1993.tb05892.x</pub-id><pub-id pub-id-type="pmcid">PMC1364555</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chew</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Woods</surname><given-names>ML.</given-names></string-name></person-group><article-title>Flucloxacillin does not achieve therapeutic cerebrospinal fluid levels against methicillin-sensitive <italic toggle="yes">Staphylococcus aureus</italic> in adults: a case report and review of the literature.</article-title><source>Int J Antimicrob Agents</source><year>2016</year>; <volume>47</volume>:<fpage>229</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">26915477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2015.12.009</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kane</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Parker</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Jordan</surname><given-names>GW</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Nafcillin concentration in cerebrospinal fluid during treatment of staphylococcal infections.</article-title><source>Ann Intern Med</source><year>1977</year>; <volume>87</volume>:<fpage>309</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">900676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-87-3-309</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fossieck</surname><given-names>BE</given-names></string-name>, <string-name name-style="western"><surname>Kane</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Diaz</surname><given-names>CR</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Nafcillin entry into human cerebrospinal fluid.</article-title><source>Antimicrob Agents Chemother</source><year>1977</year>; <volume>11</volume>:<fpage>965</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">879761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.11.6.965</pub-id><pub-id pub-id-type="pmcid">PMC352111</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yogev</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Schultz</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>Rosenman</surname><given-names>SB.</given-names></string-name></person-group><article-title>Penetrance of nafcillin into human ventricular fluid: correlation with ventricular pleocytosis and glucose levels.</article-title><source>Antimicrob Agents Chemother</source><year>1981</year>; <volume>19</volume>:<fpage>545&#8211;8</fpage>.<pub-id pub-id-type="pmid">7247377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.19.4.545</pub-id><pub-id pub-id-type="pmcid">PMC181474</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>